These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 3258516

  • 1. Investigations on the anti-HIV activity of 2',3'-dideoxyadenosine analogues with modifications in either the pentose or purine moiety. Potent and selective anti-HIV activity of 2,6-diaminopurine 2',3'-dideoxyriboside.
    Pauwels R, Baba M, Balzarini J, Herdewijn P, Desmyter J, Robins MJ, Zou RM, Madej D, De Clercq E.
    Biochem Pharmacol; 1988 Apr 01; 37(7):1317-25. PubMed ID: 3258516
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Synthesis and anti-HIV activity of various 2'- and 3'-substituted 2',3'-dideoxyadenosines: a structure-activity analysis.
    Herdewijn P, Pauwels R, Baba M, Balzarini J, De Clercq E.
    J Med Chem; 1987 Nov 01; 30(11):2131-7. PubMed ID: 3499515
    [Abstract] [Full Text] [Related]

  • 8. The antiviral activity of 9-beta-D-arabinofuranosyladenine is enhanced by the 2',3'-dideoxyriboside, the 2',3'-didehydro-2',3'-dideoxyriboside and the 3'-azido-2',3'-dideoxyriboside of 2,6-diaminopurine.
    Balzarini J, De Clercq E.
    Biochem Biophys Res Commun; 1989 Feb 28; 159(1):61-7. PubMed ID: 2538128
    [Abstract] [Full Text] [Related]

  • 9. Potentiating effect of ribavirin on the anti-retrovirus activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside in vitro and in vivo.
    Balzarini J, Herdewijn P, De Clercq E.
    Antiviral Res; 1989 Feb 28; 11(4):161-71. PubMed ID: 2545163
    [Abstract] [Full Text] [Related]

  • 10. Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine.
    Ahluwalia GS, Cooney DA, Shirasaka T, Mitsuya H, Driscoll JS, Johns DG.
    Mol Pharmacol; 1994 Nov 28; 46(5):1002-8. PubMed ID: 7969062
    [Abstract] [Full Text] [Related]

  • 11. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside.
    Balzarini J, Naesens L, Robins MJ, De Clercq E.
    J Acquir Immune Defic Syndr (1988); 1990 Nov 28; 3(12):1140-7. PubMed ID: 2123003
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enhancement of the anti-HIV-1 activity of ddAdo by coformycin, EHNA and deaza-EHNA derivatives.
    Marongiu ME, Pani A, Tinti E, Grifantini M, Franchetti P, Cristalli G, La Colla P.
    New Microbiol; 1995 Oct 28; 18(4):359-70. PubMed ID: 8590388
    [Abstract] [Full Text] [Related]

  • 19. Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.
    Cooney DA, Ahluwalia G, Mitsuya H, Fridland A, Johnson M, Hao Z, Dalal M, Balzarini J, Broder S, Johns DG.
    Biochem Pharmacol; 1987 Jun 01; 36(11):1765-8. PubMed ID: 3107569
    [No Abstract] [Full Text] [Related]

  • 20. 3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
    Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H.
    J Med Chem; 1987 Aug 01; 30(8):1270-8. PubMed ID: 3497272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.